Advanced Solid Tumor, Breast Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Gynecologic Cancer, Head and Neck Cancer, Lung Adenocarcinoma, Pancreatic Cancer
Conditions
Brief summary
This is an open-label, multicenter, First-In-Human (FIH), Phase 1a/1b study of PY159 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to Standard Of Care (including Checkpoint Inhibitors, if approved for that indication).
Detailed description
Part A: Dose escalation of PY159 alone and in combination with pembrolizumab in a standard 3+3 design Part B: Dose expansion of one or more dose levels of PY159 administered alone and in combination with pembrolizumab for predefined tumor histology
Interventions
DRUGPY159 Single agent dose level 1
Dose of PY159 as a single agent given in a standard 3+3 design.
DRUGPY159 Single agent dose level 2
Dose of PY159 as a single agent given in a standard 3+3 design.
DRUGPY159 Single agent dose level 3
Dose of PY159 as a single agent given in a standard 3+3 design.
DRUGPY159 Single agent dose level 4
Dose of PY159 as a single agent given in a standard 3+3 design.
DRUGPY159 Single agent dose level 5
Dose of PY159 as a single agent given in a standard 3+3 design.
DRUGPY159 Single agent dose level 6
Dose of PY159 as a single agent given in a standard 3+3 design.
DRUGPY159 Single agent dose level 7
Dose of PY159 as a single agent given in a standard 3+3 design.
DRUGPY159/Pembrolizumab Combination dose level 1
Dose of PY159 and given in combination with pembrolizumab
DRUGPY159/Pembrolizumab Combination dose level 2
Dose of PY159 and given in combination with pembrolizumab
DRUGPY159/Pembrolizumab Combination dose level 3
Dose of PY159 and given in combination with pembrolizumab
DRUGPY159/Pembrolizumab Combination dose level 4
Dose of PY159 and given in combination with pembrolizumab
DRUGPY159 Single agent dose expansion cohort
Dose of PY159 as a single agent given for predefined tumor histology
DRUGPY159/Pembrolizumab Combination dose expansion cohort 1
Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
DRUGPY159/Pembrolizumab Combination dose expansion cohort 2
Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
DRUGPY159/Pembrolizumab Combination dose expansion cohort 3
Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
DRUGPY159/Pembrolizumab Combination dose expansion cohort 4
Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
DRUGPY159/Pembrolizumab Combination dose expansion cohort 5
Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
DRUGPY159/Pembrolizumab Combination dose expansion cohort 6
Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
Sponsors
Ikena Oncology
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Part A: Dose escalation of PY159 alone and in combination with pembrolizumab in a standard 3+3 design; Part B: Dose expansion of one or more dose levels of PY159 administered alone and in combination with pembrolizumab for predefined tumor histology
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
KEY ELIGIBILITY CRITERIA Inclusion Criteria * Adults ≥18 years of age at the time of study consent * Subjects with any of the following eligible solid tumor diagnoses as confirmed by cytology or histology. Escalation Cohorts (Part A): Subjects with advanced solid tumors from pre-specified tumor types: * head and neck \[squamous cell carcinoma, salivary gland, thyroid\], * gynecologic \[including ovarian, fallopian, primary peritoneal, endometrial, cervical, uterine, vaginal, vulvar\], * pancreatic \[adenocarcinoma\], * lung \[adenocarcinoma and squamous cell carcinoma\] who are recurrent or refractory to platinum-based chemotherapy in addition to prior treatment with CPI Programmed Cell Death-1 (PD-1)/Programmed Cell Death-Ligand 1 (PD-L1) or who give informed consent to forego such therapy, * gastric and esophagogastric junction adenocarcinomas \[MSI low and CPI refractory MSI high\], * breast \[TNBC and HR+, HER2-\] with metastatic disease that is relapsed or refractory to at least one line of post adjuvant therapy (including a CPI-either alone or in combination, if approved for that indication, and not eligible for other targeted therapies specific for their tumor type). * Subjects must provide an original, diagnostic tumor sample to determine TREM1 expression (sites have verified source prior to screening and availability of archival tissue during screening). For Part A subjects without an archival tissue sample will only be eligible if they choose and consent to provide a CNB of a primary or metastatic lesion. * Subjects must have documented radiographic disease progression that include prior treatment with a CPI (alone or in combination), if approved for that indication. * There is no limit to the number of prior treatments * Measurable disease by RECIST 1.1. * All acute toxic effects of any prior antitumor therapy, including immunotherapy, have resolved to Grade \< 2 before the start of study drug dosing (except for alopecia or peripheral neuropathy which may be Grade \<2 or medication controlled thyroid replacement therapy). * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2.
Exclusion criteria
* Subject is a candidate for approved molecularly targeted therapy (e.g., drugs targeting EGFR,VEGF, ALK, ROS-1, NTRK, MET, RET, and BRAF V600E, HER2). Applies to enrolled subjects on both Part A and Part B of the study. * History of autoimmune disorder requiring ongoing or intermittent disease-modifying therapy excluding thyroid disease well controlled on replacement therapy. * Untreated and/or uncontrolled brain metastases Stable treated or asymptomatic brain metastases (for at least 1 month prior to enrollment may be enrolled. Subjects with stable treated or asymptomatic brain metastases receiving glucocorticoids must be on a stable dose \[≤ 2 mg/day of dexamethasone or an equivalent glucocorticoid\] for a minimum of 1month prior to enrollment.) * Uncontrolled intercurrent illness including, but not limited to, active SARS-CoV-2 infection, active or chronic bleeding event within 28 days prior to first dose of study drug or psychiatric illness/social situation that would limit compliance with study requirements as judged by treating physician. * Decompensated liver disease as evidenced by hepatic encephalopathy or coagulopathy. * Active angina or Class III or IV Congestive Heart Failure (CHF) (NYHA CHF Functional Classification System) or clinically significant cardiac disease within 12 months of first dose. of study drug, including MI, unstable angina, Grade 2 or greater peripheral vascular disease, uncontrolled HTN, or arrhythmias not controlled by medication. * Any anti-cancer therapy, including small molecules, immunotherapy, chemotherapy, monoclonal antibody therapy (with the exception of bone-modifying agents as supportive care), radiotherapy or any other agents to treat cancer within 14-21 days (dependent upon the agent and drug half-life) of first dose of study drug. Subjects with a prior history of prostate cancer on LHRH agonist are eligible provided they have no evidence of metastatic disease. Note: Other protocol defined Inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Adverse Events (AE) | 36 months | Adverse Events will be summarized by MedDRA system organ class and preferred term. Separate tabulations will be produced for all treatment emergent AEs, treatment related AEs, Serious Adverse Events (SAEs), discontinuations due to AEs, and AEs of at least NCI CTCAE grade 3 severity. |
| Dose Limiting Toxicity of PY159 (Part A only) | 21 days | Evaluation of dose-limiting toxicity (DLT). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measure PY159 maximum concentration (Cmax) | 36 months | Measure PY159 maximum concentration (Cmax) at various time points during Cycle 1. All subjects who received at least 1 dose of PY159 and have at least 1 measured concentration at a scheduled pharmacokinetics (PK) time point after start of dosing. |
| Measure PY159 concentration at the trough level (Ctrough) | 36 months | Measure PY159 concentration at the trough level (Ctrough). All subjects who received at least 1 dose of PY159 and have at least 1 measured concentration at a scheduled PK time point after start of dosing. |
| Measure PY159 Area under the curve (AUC)0-t | 36 months | Measure PY159 Area under the curve (AUC)0-t. All subjects who received at least 1 dose of PY159 and have at least 1 measured concentration at a scheduled PK time point after start of dosing for at least 1 PK analyte. |
| Measure PY159 half-life (T1/2) | 36 months | Measure PY159 half-life (T1/2). All subjects who received at least 1 dose of PY159 and have at least 1 measured concentration at a scheduled PK time point after start of dosing for at least 1 PK analyte. |
| Measure PY159 Clearance (CL) | 36 months | Measure PY159 Clearance (CL). All subjects who received at least 1 dose of PY159 and have at least 1 measured concentration at a scheduled PK time point after start of dosing for at least 1 PK analyte. |
| Incidence of Anti-Drug Antibody (ADA) formation to PY159 | 36 months | To evaluate the incidence of anti-drug antibody (ADA) formation to PY159 |
| Determining PY159 time to maximum concentration (Tmax) | 36 months | Determining PY159 time to maximum concentration (Tmax) during Cycle 1. |
| Objective response rate (ORR) | 36 months | The incidents of ORR is defined as either a complete or partial response (PR) per RECIST. Subjects with no baseline data will be considered no responders. ORR will be summarized by dose, tumor type, and overall. ORR will be summarized descriptively. |
| Clinical Benefit Rate (CBR) | 36 months | Defined as the percentage of subjects who have achieved complete response (CR), partial response (PR) and stable disease (SD). |
| Duration of response (DOR) | 36 months | DOR will be calculated to determine durability. DOR will be measured from the time by which the criteria for CR or PR-whichever is recorded first-are met until the first date by which recurrent or progressive disease is objectively documented. DOR will be assessed using KAPLAN-MEIER methods. |
| Measure PY159 Volume at Steady State (Vss) | 36 months | Measure PY159 Volume at Steady State (Vss). All subjects who received at least 1 dose of PY159 and have at least 1 measured concentration at a scheduled PK time point after start of dosing for at least 1 PK analyte. |
| Measure PY159 concentration at the end of infusion (CEOI) | 36 months | Measure PY159 concentration at the end of infusion (CEOI) after the first dose. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Progress free survival (PFS) | 36 months | PFS will be measure from entry onto the study until disease progression or death from any cause. PFS will be assessed using KAPLAN-MEIER methods. |
| Overall survival (OS) | 36 months | The duration of overall survival (OS) will be measured from the time of first study drug administration until the date of death. OS will be assessed using KAPLAN-MEIER methods. |
Countries
United States
Outcome results
None listed